US approves Biogen Alzheimer's drug
US regulators have approved Biogen's aducanumab as the first treatment to attack a likely cause of Alzheimer's disease, sending its shares soaring, despite controversy over whether the clinical evidence proves the drug works.
World
• 08 Jun 21